Middle East Live

TAIPEI, Taiwan-Wednesday 26 May 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- TAITRA today announced its COMPUTEX 2021 opening keynote on May 31 featuring Intel led by Executive Vice President and Chief Revenue Officer Michelle Johnston Holthaus.

Beginning at 10 a.m. Taipei Standard Time (7 p.m. Pacific Daylight Time, Sunday, May 30, 2021), the virtual Intel keynote will provide a firsthand look at how the strategies of new CEO Pat Gelsinger, along with the forces of a rapidly accelerating digital transformation, are unleashing a new era of innovation at Intel — right when the world needs it most. The keynote livestream and replay can be watched here.

Johnston Holthaus will welcome Intel’s Steve Long, corporate vice president of Client Computing Group Sales, and Lisa Spelman, corporate vice president and general manager of the Xeon and Memory Group, to outline how Intel innovations help expand human potential by expanding technology’s potential. This includes collaborating with partners to drive innovation across the technology ecosystem — from the datacenter and cloud to connectivity, artificial intelligence, and the intelligent edge.

For Intel at COMPUTEX 2021, please visit: https://www.computextaipei.com.tw/en/index.html.

About COMPUTEX TAIPEI (also called COMPUTEX):

Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.

About COMPUTEX 2021 Hybrid:

As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. This year, COMPUTEX will launch the "COMPUTEX 2021 Hybrid". As the event organizer, the Taiwan External Trade Development Council (TAITRA) introduces AI computing capabilities to the exhibition to shape COMPUTEX as a global model and aims to deliver an exceptional exhibition experience by presenting the online platform — #COMPUTEXVirtual.

About TAITRA:

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005495/en/

Contacts
Press:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>

Permalink : https://www.aetoswire.com/news/intel-computex-keynote-promoting-innovation-unleashed/en

～Strategic Acquisition to Expand its BPH Portfolio into In-office Treatment～

TOKYO & HAMBURG, Germany & CENTER VALLEY, Pa. -Friday 28 May 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February, 2021. Through this acquisition, Olympus expands its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidifies its position as a leader in the field of urological devices.

Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of BPH. The company’s flagship product “iTind” has received U.S. FDA de Novo authorization and a European CE mark. With its initial Medi-Tate investment, Olympus has had the right of distribution since November 2018.

The incidence of BPH, one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (“LUTS”), is expected to increase as the general global population gets older. According to the American Urological Association, BPH is a condition that nearly 80% of men will face in their lifetime and that ratio is higher in older ages.ⅰ Medication and surgical treatment have been among the usual treatment options for BPH, and in recent years, more minimally invasive surgical treatment devices have come to the market.

Olympus is a market leader providing devices for BPH treatment such as resectoscopes and a wide variety of electrodes. By adding the non-ablative BPH treatment device iTind, which allows patients to maintain their sexual function, to its portfolio, Olympus can provide urologists more treatment options according to the symptoms and needs of their patients, ranging from in-offices day treatment to surgical therapies in hospitals.

Nacho Abia, Chief Operating Officer of Olympus Corporation, said, “the acquisition of Medi-Tate aligns with our corporate strategy of focusing on three priority therapeutic areas within our Therapeutic Solutions Division — gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices. Medi-Tate’s innovative products offer a truly minimally invasive treatment option for patients and flexibility in the delivery of care for healthcare professionals.”

Ido Kilemnik, Chief Executive Officer of Medi-Tate, commented, “We believe Olympus appreciates our focus on long-term clinical results and dedication of the entire Medi-Tate team. We are pleased to be joining Olympus, which shares our vision of making iTind the global standard for BPH treatment. We are excited to be collaborating with Olympus in our effort to enhance the patients’ quality of life.”

Minimally invasive treatment enabled by iTind

iTind, a temporarily implanted nitinol device, supports the relief of lower urinary tract symptoms (LUTS) due to BPH. The iTind treatment is performed by an urologist in an outpatient hospital, ambulatory surgery center or in a physician’s office, where the iTind device is placed in the prostate in a folded configuration. The device slowly expands and exerts gentle pressure at three precise points to reshape the prostatic urethra and bladder neck. After five to seven days, the device is completely removed, leaving a wider opening through which urine can flow for the relief of BPH symptoms.

i American Urological Association, Benign Prostatic Hyperplasia. Available at:
https://www.auanet.org/education/auauniversity/medical-student-education/medical-student-curriculum/bph

About Medi-Tate

Medi-Tate is an Israeli medical device company dedicated to improving men’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and the FDA cleared for use in the United States. For more information, visit www.medi-tate.com.

About Olympus’ Therapeutic Solutions business

In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Starting with its early contributions to the development of the polypectomy snare, Olympus’ Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005341/en/

Contacts
For questions or additional information:

Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

United States
Jennifer Bannan
+1 412-403-8742
jennifer.bannan@olympus.com

Japan and APAC
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com

Permalink : https://www.aetoswire.com/news/olympus-acquires-israeli-medical-device-company-medi-tate-to-drive-global-urology-business-growth/en

Contacts

Shirin Zemmo

Email: shirin@matrixdubai.com

Phone: +97143430888 

Permalink : https://www.aetoswire.com/news/matrix-pr-joins-the-plexus-pr-groupnbsp/en

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

SLIEMA, Malta-Saturday 17 April 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- The Board of Directors of Cryptology Asset Group p.l.c. (ISIN: MT0001770107; Ticker: CAP) today resolved to increase the share capital of the Company by 128,375 new shares and to sell 31,625 treasury shares which is the entire position Cryptology holds of own shares after the buyback done over the last months. Shareholders' subscription rights to the new shares and the treasury shares are excluded.

The Company has entered into binding subscription agreements for the entire amount of in total 160,000 shares with several institutional investors. Closing of the transaction is expected for end of April 2021.

The capital increase will be carried out in cash contributions and by partially utilizing the existing authorized capital. The share capital of the Company is to be increased from EUR 2,732,500 to EUR 2,860,875 by issuing 128,375 new bearer shares of the Company ("New Shares"). The New Shares will be issued with a pro rata amount of capital stock of EUR 1.00 per share and with full dividend rights from 1 January 2021. The New Shares and treasury shares will be offered at a fixed price of EUR 200.00 per share. Following their issue, the New Shares will be included in the existing listing on the primary market of the Düsseldorf Stock Exchange.

The net proceeds from the capital increase and the funds received from the sale of treasury shares of in total 32,000,000 will be used to invest in new portfolio companies from the Cryptology pipeline. The company is also exploring the acquisition of crypto assets, such as Bitcoin, as part of its treasury management strategy.

Language:    English
Company:    Cryptology Asset Group PLC
     Beatrice 66 & 67, Amery Street
     SLM 1707 Sliema
     Malta
E-mail:    info@cryptology-ag.com
Internet:    cryptology-ag.com
ISIN:    MT0001770107
WKN:    A2JDEW
Listed:    Regulated Unofficial Market in Dusseldorf
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005726/en/

 
Contacts
Cryptology Asset Group p.l.c.
Jefim Gewiet (COO)
Tel:+356 799 85 85 1
Email: jg@cryptology-ag.com
66/67, Beatrice, Amery Street
Sliema SLM 1707 Malta
E-mail: info@cryptology-ag.com

Permalink : https://www.aetoswire.com/news/cryptology-asset-group-plc-resolves-a-cash-capital-increase-and-sale-of-treasury-shares/en

Wider and Clearer View for More Facts

DUBAI, United Arab Emirates-Monday 24 May 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Hytera, as a world leading provider of professional communications technologies and solutions, brings body worn cameras (BWC) to a new level with innovative hardware and software design, convergence with push-to-talk technology, and integration with control room solution.

Hytera has full series of 4G or LTE body worn cameras which can capture HD video to provide evidence for trials. More importantly, they are able to send live video back to the control center over 4G network. This helps the dispatcher know exactly what is happening, enhance real-time situational awareness and facilitate decision-making. Hytera has launched a comprehensive solution including the body worn camera, integrated device station and digital evidence management platform.

Designed for the field with evidence management in mind, the VM780 takes RVM Bodycams to the next level with the most advanced range of features available, including a 2.8” touch display, 3G/ 4G & Wi-Fi for real time transmission anywhere, GPS built-in and Push-to-talk over cellular (PoC) application compatibility. The device features a 216° rotatable camera and powerful 3-watt speaker to deliver loud and clear audio during the call, even in highly noisy environments. It also supports NFC and Bluetooth connectivity, AES256 advanced encryption technology, and simple charging and programming via the micro-USB interface.

The VM580D is suitable for both mission critical and commercial users. It’s slim (only 20mm thick), lightweight and easy to operate with one hand for photo taking, audio and video recording. It can share real-time GPS location information over LTE, 3G, and Wi-Fi networks. The device also serves as a PoC radio, which can be used for evidence collection simultaneously with a PoC platform such as Hytera HyTalk.

Hytera also provides various related software and hardware including storage, evidence collection, evidence classification, and dispatch platform, etc. Hytera is one of the few companies which can provide E2E body worn cameras solution to customers.

It's known to all that it is not uncommon for the officers to face the confrontations or dispute from the public during onsite law enforcement. Public safety and governmental institutions have increasingly advocated or legislated the use of BWC for promoting law enforcement transparency, deterring the violence and increasing trial efficiency. For example, a Dubai ruler issued a resolution to authorize its police to use security cameras in public areas to fulfill its duties including handling traffic violations and ensuring effective security. Hytera BWC Solution has been adopted by government and industry customers including the Shanghai Police and Macau Police to restore the truth of what happened with the first-person recording, voice and video, and bring better transparency and accountability to help improve law enforcement legitimacy.

Learn more at http://www.hytera.ae.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005363/en/

Contacts
Jia Liu
Jia.Liu@hytera.com

Permalink : https://www.aetoswire.com/news/hytera-brings-body-worn-camera-to-a-new-level/en

• New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.

• The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvement.

• The Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020.

INGELHEIM, Germany & COPENHAGEN, Denmark-Tuesday 13 April 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH). The compound was in-licensed from Zealand in 2011 and is being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus. The once-weekly therapy may offer additional benefits on both chronic weight management, and NASH improvement and prevention of the progression to cirrhosis compared to currently available treatments with mono GLP-1 agonist compounds. BI 456906 is part of Boehringer Ingelheim’s growing portfolio in the obesity and NASH disease areas.

“Obesity and NASH are areas of high unmet medical need, with limited approved treatments currently available. They are associated with lower quality of life and increased mortality,” explains Prof. Arun J. Sanyal, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine in Richmond, Virginia. “I hope that this new approach will bring a much-needed treatment option for HCPs and people afflicted with obesity or NASH.”

Boehringer Ingelheim and Zealand have a fruitful longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. “We are very excited to see the initiation of Phase 2 trials of BI 456906 for obesity and NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining GLP-1 and glucagon agonism mechanistically, we believe our dual agonist has the potential to achieve increased weight loss, via improvement of the patient’s metabolism, and also has potential to alleviate NASH by reducing upstream steatosis.”

“Our cardiometabolic research and development is focusing on discovering novel treatments for obesity and non-alcoholic steatohepatitis (NASH), to meet the large unmet need among these groups,” explains Waheed Jamal, MD, Head of Cardiovascular, Metabolic and Respiratory Medicine at Boehringer Ingelheim. “We are exploring a number of unique approaches with great potential to help people living with obesity or NASH. We believe dual agonists are next generation drug candidates with a potential for higher efficacy in weight loss and NASH improvement/cirrhosis prevention.”

Under the terms of the GLP-1/glucagon dual agonist licensing agreement, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is entitled to receive up to EUR 345 million in outstanding milestone payments. No milestone payments are due with the initiations of these Phase 2 studies. The agreement also carries high-single digit to low-double digit percentage royalties on global sales.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/clinical-phase2-trials-nash-and-obesity

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005636/en/

Contacts
Boehringer Ingelheim
Dr. Birgit Leimer
Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
E-Mail: press@boehringer-ingelheim.com

Zealand Pharma
David Rosen
Argot Partners
E-Mail: media@zealandpharma.com

Permalink : https://www.aetoswire.com/news/boehringer-ingelheim-and-zealand-pharma-advance-to-phase-2-clinical-testing-in-nash-and-obesity/en

MEXICO CITY-Wednesday 19 May 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”).

The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the Tender Offer will be promptly following the Expiration Date, expected to be no later than three business days following the Expiration Date, or May 26, 2021, unless extended (such date, as the same may be extended, the “Settlement Date”).

Holders of Securities who (i) validly tender their Securities on or prior to the Expiration Date or (ii) deliver a properly completed and duly executed Notice of Guaranteed Delivery at or prior to the Expiration Date and tender their Securities at or prior to 5:00 p.m. (New York City time) on the second business day after the Expiration Date, which is expected to be May 25, 2021, will be eligible to receive US$1,055.75 for each US$1,000 principal amount of Securities (the “Tender Consideration”). In addition to the Tender Consideration, holders whose Securities are accepted for purchase will be paid the accrued and unpaid interest on such Securities to, but not including, the Settlement Date (the “Accrued Coupon Payment”), together with any additional interest. The Tender Consideration and the Accrued Coupon Payment will be payable in cash. Interest will cease to accrue on the Settlement Date for all Securities purchased in the Tender Offer.

Orbia’s obligation to accept and pay for the Securities validly tendered and not validly withdrawn pursuant to the Tender Offer is subject to the satisfaction of certain customary conditions described in the Offer to Purchase, including that Orbia will not be obligated to consummate the Tender Offer upon the occurrence of an event or events or the likely occurrence of an event or events that would or might reasonably be expected to prohibit, restrict or delay the consummation of the Tender Offer or materially impair the contemplated benefits to Orbia of the Tender Offer. These conditions may be waived by Orbia, in whole or in part, at any time and from time to time, in its sole discretion, subject to applicable law. The Tender Offer is not contingent upon the tender of any minimum principal amount of Securities.

Subject to applicable law, the Tender Offer may be amended, extended or, upon failure of a condition to be satisfied or waived prior to the Expiration Date, terminated. If Orbia terminates the Tender Offer, it will give prompt notice to the tender agent for the Tender Offer and all Securities tendered will be returned promptly to the tendering holders thereof. With effect from such termination, any Securities blocked in DTC will be released. Subject to the results of the Tender Offer, we currently intend to send a notice of redemption with respect to any outstanding Securities pursuant to their terms as promptly as practicable following the Settlement Date. This statement of intent shall not constitute a notice of redemption under the indenture.

Holders are advised to check with any bank, securities broker or other intermediary through which they hold Securities as to when such intermediary would need to receive instructions from such holder in order for that holder to be able to participate in, or withdraw their instruction to participate in, a Tender Offer, before the deadlines specified herein and in the Offer Documents. The deadlines set by any such intermediary and DTC for the submission and withdrawal of tender instructions will also be earlier than the relevant deadlines specified herein and in the Offer Documents.

Orbia has retained BBVA Securities Inc. and Morgan Stanley & Co. LLC to act as dealer managers in connection with the Tender Offer (the “Dealer Managers”). D.F. King & Co., Inc. will act as the tender agent and information agent for the Tender Offer.

Any questions or requests for assistance regarding the Tender Offer may be directed to BBVA Securities Inc. at +1 (800) 422 8692 (toll-free) and +1 (212) 728 2446 (collect) and Morgan Stanley & Co. LLC at +1 (800) 624-1808 (toll-free) and +1 (212) 761-1057 (collect). Requests for additional copies of the Offer Documents may be directed to D.F. King & Co., Inc. at + (800) 848-2998 (toll-free) or +(212) 269-5550 (collect). The Offer Documents can be accessed at the following link: www.dfking.com/orbia.

This press release is for informational purposes only. This press release shall not constitute an offer to purchase or sell or the solicitation of an offer to sell or purchase any securities.

The Tender Offer is being made solely pursuant to the Offer Documents. The Offer Documents have not been filed with, and have not been approved or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Offer Documents or any other documents related to the Tender Offer, and it is unlawful and may be a criminal offense to make any representation to the contrary. The Tender Offer is not being made to holders of Securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Tender Offer to be made by a licensed broker or dealer, the Tender Offer will be deemed to be made on behalf of Orbia by the Dealer Managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.

THE INFORMATION CONTAINED HEREIN AND IN THE OFFER TO PURCHASE IS EXCLUSIVELY ORBIA’S RESPONSIBILITY AND HAS NOT BEEN REVIEWED OR AUTHORIZED BY THE MEXICAN NATIONAL BANKING AND SECURITIES COMMISSION (COMISIÓN NACIONAL BANCARIA Y DE VALORES, THE “CNBV”). ORBIA HAS NOT FILED WITH THE CNBV A REQUEST FOR AUTHORIZATION OF THE TENDER OFFER. THE TENDER OFFER DOES NOT CONSTITUTE A PUBLIC OFFERING IN MEXICO AND IT MAY NOT BE PUBLICLY DISTRIBUTED IN MEXICO. THE TENDER OFFER MAY ONLY BE MADE AVAILABLE IN MEXICO TO INVESTORS THAT QUALIFY AS INSTITUTIONAL OR ACCREDITED INVESTORS (INVERSIONISTAS INSTITUCIONALES OR INVERSIONISTAS CALIFICADOS), SOLELY PURSUANT TO THE PRIVATE OFFERING EXEMPTION SET FORTH IN ARTICLE 8 OF THE MEXICAN SECURITIES MARKET LAW (LEY DEL MERCADO DE VALORES) AND REGULATIONS THEREUNDER. NEITHER THE OFFER TO PURCHASE, THE NOTICE OF GUARANTEED DELIVERY OR ANY OTHER OFFERING MATERIALS MAY BE PUBLICLY ADVERTISED, MARKETED, DISTRIBUTED IN MEXICO. FURTHERMORE, THE CNBV HAS NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS OFFER TO PURCHASE. IN MAKING A DECISION AS TO WHETER TO TENDER ANY OF THEIR SECURITIES, ALL HOLDERS MUST RELY ON THEIR OWN REVIEW AND EXAMINATION OF THE TERMS OF THE TENDER OFFER.

The communication of this press release and any other documents or materials relating to the Tender Offer is not being made and such documents and/or materials have not been approved by an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000. This press release and any other documents or materials relating to the Tender Offer are for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Order, (iii) are members or creditors of certain bodies corporate as defined by or within Article 43(2) of the Order, (iv) are outside the United Kingdom, or (v) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the offer to purchase any securities may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). This press release and any other documents or materials relating to the Tender Offer are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release and any other documents or materials relating to the Tender Offer are available only to and will be engaged in only with relevant persons.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are information of a non-historical nature or which relate to future events and are subject to risks and uncertainties. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions. Orbia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or for any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005599/en/

Contacts
Investors
Javier Luna, Capital Markets and Investor Relations Director
+52 55 5366 4151
javier.luna@orbia.com

Media
Kacy Karlen, Corporate Communications Director
+1 865-410-3001
kacy.karlen@orbia.com

Permalink : https://www.aetoswire.com/news/orbia-announces-cash-tender-offer-for-its-outstanding-notes-due-2022/en

Certification recognizes Company’s excellence in building a high trust – high performance culture for all employees

LAS VEGAS-Saturday 22 May 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Rimini Street India Operations Private Ltd. has earned the designation of Great Place to Work-CertifiedTM. Based on validated employee feedback gathered using Great Place to Work’s rigorous, data-driven methodology, the certification confirmed that 94% of employees believe that Rimini Street India excelled in building a high-trust Company culture and creating a positive work environment for all.

As part of the assessment process, Rimini Street India employees participated in Great Place to Work’s Trust Index© survey to assess the organization’s overall cultural landscape and employee engagement levels. Secondly, a Culture Audit© detailed Rimini Street’s best practices in employee engagement across the entire employee lifecycle, which include employee induction practices and buddy programs to engage new employees, available training and certifications and a formal career growth program to encourage career opportunities. Additional engagement programs include employee wellness programs such as health camps, yoga and fitness workshops, annual sports events, group activities and a regular cadence of employee surveys to connect and gather feedback. Employees scored Rimini Street highly across five key areas of engagement including credibility, respect, fairness, pride and camaraderie.

India’s Great Place to Work® Institute evaluates and recognizes companies with best-in-class workplaces and company culture. Rimini Street’s certification puts a spotlight on its diligence to build a work culture that engages and enhances the employee experience and promotes the values of credibility, respect, fairness, pride, and camaraderie.

Rimini Street India currently employs over 400 professionals working in Bengaluru, Hyderabad and other cities across India. Rimini Street India employees work in finance, HR, legal, IT, global security, marketing, sales operations, client onboarding, software development, quality systems, technology innovation, artificial intelligence, global operations and support delivery. The Rimini Street India team is a significant contributor to the Company’s global growth and unmatched 4.9/5.0 average client satisfaction for cases (where 5.0 is “excellent”).

“Being Great Place to Work-Certified is a rewarding endorsement from our employees recognizing Rimini Street’s commitment to fostering a work environment that is inclusive, engaging and supportive,” said Raju Gadiraju, managing director, Rimini Street India Operations Private Ltd. “Rimini Street is a great place to work, not only due to the programs we have in place, but because our people are deeply committed to creating a collaborative and nurturing workplace. Together, they reinforce Rimini Street as an employer of choice in our industry and ensure a happier, well-balanced team that helps drive business results and make a difference to our clients and communities in which we live and work.”

The Great Place to Work® Institute is a highly acclaimed international organization with an employee experience platform for evaluating and identifying companies with best practices and programs in human resource management and company culture. Every year, more than 10,000 organizations from over 60 countries partner with Great Place to Work Institute for assessment, benchmarking and planning actions to strengthen their workplace culture. Their methodology is recognized as rigorous and objective, and is considered the gold standard for defining great workplaces across business, academia and government organizations.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,000 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on May 10, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

©2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005829/en/

Contacts
Michelle McGlocklin
Rimini Street, Inc.
+1 925 523-8414
mmcglocklin@riministreet.com

Permalink : https://www.aetoswire.com/news/rimini-street-india-certified-as-great-place-to-workreg-company/en

Dubai, United Arab Emirates-Saturday 22 May 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Recently, a 15-meter-high, 45-meter-wide giant screen in Dubai scrolled a poster with the theme of “Pineapple in Guangdong, China, Fragrant Everywhere.” Guangdong’s pineapples enter the world, which fully demonstrates the momentum of the internationalization of the brand of Guangdong agricultural products.

The pineapples in China are most famous in Guangdong, and the pineapples in Guangdong are most famous in Xuwen. Known as the “hometown of pineapple,” Xuwen, Zhanjiang, Guangdong, accounts for about 38% of China’s pineapple production and is the largest pineapple producing area in China. Recently, Xuwen’s pineapples, with their golden appearance, full flesh, juicy sweetness and rich nutrition, have not only been listed on the Internet hot search, but also on a special high-speed train, crossing 14 provinces and cities such as Beijing, Shanghai and Gansu. A variety of pineapple dishes enter the world's dining tables, awakening the taste buds on the tongue and bringing new delicious memories.

To enhance the popularity of Guangdong pineapples and help farmers open up their products for sale, Guangdong promoted its high-quality pineapple brand to overseas markets by forming buyers in the sales area and training purchasing assistants in the production area. Following the export to Japan, Russia, Kyrgyzstan and other countries and regions, Guangdong’s pineapple will also expand markets in West Asia, South Asia and so on as well as broaden the new blue sea in the world for the international spread of Guangdong agricultural products bloom brilliant colors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210520006133/en/

Contacts
Ziyu Yan
Tel: +86139 2221 8503
Email: 706955815@qq.com

Permalink : https://www.aetoswire.com/news/the-poster-of-ldquopineapple-in-guangdong-china-fragrant-everywhererdquo-was-displayed-at-the-wafi-landmark-in-dubai/en